Podcasts about international myeloma working group

In this episode of ASTCT Talks, Dr. Muhammad Salman Faisal is joined by Dr. Jens Hillengass. Dr. Hillengass discusses the latest advancements in CAR T cell therapy, focusing on its application in early-line settings following the results of the CAR-TITUDE 4 and KarMMa-3 trials. Tune in as he shares insights on the efficacy, patient selection and future directions of CAR-T cell therapy in multiple myeloma. This episode is supported by Johnson & Johnson. Don't miss out on this informative discussion with one of the leading experts in the field. About Dr. Jens Hillengass Jens Hillengass, MD, PhD, is Professor of Oncology and Chief of the Myeloma and Amyloidosis Service at Roswell Park Cancer Institute, Buffalo, NY. Previously, he was the head of the autologous stem cell transplant program and the deputy chief of the multiple myeloma section at the University Hospital of Heidelberg, Germany. He earned his medical degree, residency, and fellowship at Heidelberg University, and completed a research fellowship at the National Cancer Institute. Dr. Hillengass co-chairs the bone and imaging group of the International Myeloma Working Group and serves on the Multiple Myeloma guideline committee at the National Comprehensive Cancer Network. About Dr. Muhammad Salman Faisal Dr. Muhammad Salman Faisal is currently a fellow at Roswell Park Comprehensive Cancer Center, in his third year of training, with keen interest in myeloma, CAR-T and access to care.

Multiple Myeloma Update — Part 1: Our interview with Dr Rajkumar highlights the following topics as well as cases from his practice: Updated risk-stratification model for smoldering multiple myeloma (MM) incorporating the revised International Myeloma Working Group diagnostic criteria; therapeutic approach for standard- versus high-risk smoldering MM (00:00) Subcutaneous versus intravenous daratumumab administration for MM (05:28) Efficacy and tolerability of the recently FDA-approved regimen of daratumumab in combination with lenalidomide and dexamethasone for patients with previously untreated MM not eligible for autologous stem cell transplantation (ASCT) (06:52) Activity, tolerability and ongoing trials of carfilzomib- and bortezomib-based triplet regimens for newly diagnosed MM (08:55) Results of the Phase III CASSIOPEIA study: Bortezomib/thalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM eligible for ASCT (12:39) Case: A man in his early 80s with MM initially treated with lenalidomide/bortezomib/dexamethasone and maintenance lenalidomide experiences relapse 2 years later (15:02) Benefits and risks of the Bcl-2 inhibitor venetoclax in combination with bortezomib/dexamethasone for relapsed/refractory (R/R) MM with and without the t(11;14) translocation on the Phase III BELLINI trial (16:43) Proposed mechanism of venetoclax-associated mortality in MM (19:35) Understanding the clinical role and limitations of surrogate endpoints for overall survival (24:29) Perspective on the possible design flaws in the BELLINI trial (28:08) CME information and select publications  

Jens Hillengass discusses the new International Myeloma Working Group consensus guidelines on optimal use of imaging methods for monoclonal plasma cell disorders.

A new clinical trial is open combining low dose melphalan, a drug commonly used at high doses for stem cell transplant, and high dose intravenous Vitamin C. Learn more about how these two treatments work synergistically and why they have been combined in a clinical trial at the University of Iowa. The University of Iowa has unique experience with IV Vitamin C and Dr. Yogesh Jethava joins Myeloma Crowd Radio to share this fascinating open study now enrolling patients.  Dr. Yogesh Jethava is Associate Professor and Director of the Multiple Myeloma program as well as Associate Director of the Blood and Marrow Program at the University of Iowa. Prior to this appointment, he was director of the Bone Marrow and Stem Cell Transplant Services Division of Hematology Oncology at the Winthrop P. Rockefeller Cancer Institute at University of Arkansas for Medical Sciences or UAMS where he established the first fully functional allo transplant unit. There, he was Director and Attending Physician for the Leukemia and Lymphoma Subspecialty Clinic.   Dr. Jethava is an International Myeloma Working Group member and part of the EMBT malignancy working group and is a member of the Experimental Therapeutics groups and others. He reviews abstracts for publications like blood leukemia in the Blood Cancer Journal, and he is also working on studies that involves high dose vitamin C infusions for plasma cell disorders like myeloma. 

It's Myeloma Awareness Month, and to spread the word we are releasing 2 concurrent episodes- MGUS and Myeloma. This week you are in the outpatient GIM clinic and our episode is all about Monoclonal Gammopathy of Undetermined Significance.  We delve deeper into what it means to order SPEP, UPEP, serum immunofixation and serum free light chains, and we overview the International Myeloma Working Group definitions of MGUS. As always, we have an associated infographic as well as relevant resources at www.theinternatwork.com.This episode was written by Dr. Zahra Merali (Internal Medicine Resident) and reviewed by Dr. Laura Habib (Malignant Hematology Fellow), Dr. Mohammed Aljama (Malignant Hematologist) and Dr. Rajendar Hanmiah (General Internist). Infographic by Nikhita Singhal. 

Professor Jesus San Miguel (University Hospital of Salamanca, Salamanca, Spain) outlines how the role of minimal residual disease (MRD) negativity has evolved to become part of the central narrative of how multiple myeloma is treated. In the 1980s a cure in multiple myeloma was considered unattainable due to the small proportion of patients achieving a complete response. However, with the introduction of new agents the landscape has changed. This movement led to the International Myeloma Working Group recently publishing a consensus criteria for response and minimal residual disease assessment in multiple myeloma. In this review several aspects of disease response assessment are clarified, as well as endpoints for clinical trials and future directions. Professor San Miguel adds that while the concept of MRD is usually associated with depth of treatment response in multiple myeloma, there could be growing utility around measuring treatment efficacy with long term follow up, as seen in other diseases. The impact that MRD negativity has on patients is then discussed, with clear associations between patients being MRD negative and a positive response. Whilst questions remain, the potential of MRD negativity being a surrogate marker for cure in multiple myeloma is a distinct possibility.

Michele Cavo discusses the International Myeloma Working Group’s recommendations on the use of 18F-FDG PET/CT for patients with multiple myeloma and other plasma cell dyscrasias.

Shaji Kumar discusses updated consensus criteria from the International Myeloma Working Group for response and minimal residual disease assessment in multiple myeloma.

Join us as we talk with renown myeloma expert Dr. Jesus San Miguel of the University Hospital of Salamanca about high risk myeloma, recent findings of the International Myeloma Working Group and his work on minimal residual disease.